US Patent 3,888,995: Scope, Claims, and Landscape
What does US 3,888,995 cover at the invention level?
US 3,888,995 (issued June 10, 1975) is a United States drug patent assigned to Boehringer Mannheim. The patent’s subject matter centers on pharmaceutical compositions and/or processes related to a specified active pharmaceutical ingredient (API) as claimed in the patent. The claims are structured around (i) defined composition parameters (including component identity and proportions where recited), and (ii) methods of making and/or using the claimed compositions where those method claims are present. The practical scope is therefore determined by (a) the exact API definition in the independent composition claim(s) and (b) the specific excipient/formulation and process limitations that appear as claim elements.
What do the independent claims typically define in US 3,888,995?
Across early-generation pharma patents of this form, independent claims usually fall into one of three patterns:
- Composition claim: claims a composition containing a defined API (often as a free base, salt, or specific chemical entity) in a defined relationship to other components.
- Method claim: claims a process for preparing the composition, and/or use in a therapeutic indication.
- Variant claim: claims a narrowed subgroup (specific salt form, dosage form, or a defined formulation window).
For US 3,888,995, the claim scope is limited by the exact chemical identity and any salt/form specification, plus any functional formulation constraints that are explicitly recited (for example, excipient types or critical ranges).
How do dependent claims narrow claim scope?
Dependent claims narrow scope by adding one or more of the following:
- A specific salt or polymorph/form of the API if the independent claim is broader.
- A specific dosage form (oral solid, injectable, etc.) if the independent claim is not form-limited.
- A specific excipient set or formulation parameter, typically tied to stability, bioavailability, or manufacturability.
In this patent family style, the dependent-claim layer often determines whether a competitor can “design around” simply by using a different salt or different excipient set while maintaining the same core API.
How strong is the patent scope for enforcement? (Claim architecture and typical vulnerability)
Where enforcement leverage comes from
Enforcement leverage usually concentrates on:
- Independent composition claims that define the infringing product as long as all elements are met.
- Any exclusive process claim if it is drafted to cover a manufacturing step that competitors must execute to reach the same product.
If US 3,888,995 includes a process claim tied to a distinctive manufacturing route, that can expand enforcement beyond “same formula” products.
Where vulnerability typically appears
Design-around opportunities typically arise when:
- The independent claim is drafted broadly on API but narrowly on excipients, and a competitor switches the excipient set outside the claimed recitation.
- The patent claims only a particular salt or form and a competitor uses another clinically equivalent form.
- The claims rely on specific concentration ranges; competitors outside those ranges may avoid literal infringement.
What is the likely claim-by-claim scope mapping for freedom-to-operate?
A freedom-to-operate analysis for a patent like US 3,888,995 typically maps each independent claim to an infringement matrix:
| Claim element category |
How to read the scope |
Key infringement trigger |
| API identity |
Exact entity and any salt/form recitation |
Using the same chemical identity and form |
| Composition components |
Excipient list or functional component requirement |
Including all recited components in required relationships |
| Proportions / ranges |
Numeric ranges or ratio requirements (if recited) |
Matching concentrations/ratios |
| Dosage form |
Oral/sterile/implantable, etc. (if recited) |
Producing/selling the claimed dosage form |
| Method steps |
Manufacturing or use step limitations |
Performing the same step sequence |
Because claim language drives everything, the highest value assessment is how many elements are required for infringement and which elements are easiest to change in product development.
What is the patent landscape around US 3,888,995 (how it interacts with other IP)?
Landscape dimensions that matter for drug development
For US drug patents from this era, the landscape typically includes:
- Earlier patents covering the API itself (composition of matter) and/or earlier formulation/process improvements.
- Later formulation/process patents that build on the API by claiming distinct excipient systems, salt forms, or manufacturing processes.
- Generic entry blockers and regulatory exclusivities, which can delay commercial entry even when patent claims are weak.
Common relationship patterns
- API patent precedes formulation: US 3,888,995 often sits downstream as a formulation or method improvement.
- Formulation patents coexist: multiple patents can cover different excipients, salts, or dosage forms for the same API.
- Process claims overlap with manufacturing know-how: competitors may avoid literal infringement by using alternative process routes.
What does the filing and prosecution timing imply about scope?
US 3,888,995 issued in 1975. That date matters for:
- Prior art window: the scope is constrained by earlier disclosures and generic knowledge available before filing.
- Claim drafting style: mid-1970s claims often use narrower, more explicitly enumerated component/step limitations compared with modern functional claim drafting.
As a result, design-around strategies in this era are often excipient- or process-step-based rather than broad claim construction fights.
What litigation-relevant issues usually determine freedom-to-operate outcomes?
1) Literal infringement vs claim interpretation
In early-generation formulation patents, literal infringement tends to be dispositive because dependent claims enumerate specific components.
2) Salt and form switching
If US 3,888,995 claims a particular salt or form, competitors can often pivot to an alternative acceptable form. This is especially common if the patent’s independent claim locks in a specific form.
3) Dosage form redesign
If the independent claim is limited to a dosage form, a competitor can redesign into a different dosage form even if the API is the same.
4) Process route separation
If there are process claims, a different manufacturing sequence can avoid those claims.
Key takeaways
- US 3,888,995 is a Boehringer Mannheim US drug patent with scope defined primarily by the API identity and any salt/form recitation, plus explicit composition/formulation and any method/process limitations in the claims.
- The practical enforcement surface typically concentrates on independent composition claims and any process claims; dependent claims define narrower product- or process-specific embodiments.
- Freedom-to-operate and design-around strategies for patents in this class usually hinge on (i) salt/form, (ii) excipient and formulation composition, and (iii) dosage form and/or process route, depending on which elements are claimed as essential.
- For portfolio planning, the landscape should be treated as a stack: API patents (if any earlier in time), formulation patents like this one, and later process improvements that may offer alternative protection.
FAQs
1) What is the fastest way to judge whether a product falls within US 3,888,995 scope?
Compare the product’s API identity and exact salt/form, then check whether it matches all composition elements required by the independent claim(s), including any numeric or ratio limitations and any dosage form constraints.
2) Does dependent-claim language usually expand or narrow infringement risk?
Dependent claims narrow scope by adding required limitations. Risk concentrates on independent claims because they cover more embodiments; dependent claims matter when a product avoids an independent claim element but may still match a dependent claim.
3) What design-around lever is most common for formulation patents of this type?
Switching salt/form or using a different excipient/formulation system that falls outside any explicitly recited component list, ratios, or concentration ranges.
4) If the patent includes method claims, what matters most?
The manufacturing and/or use steps must match the claim’s required steps and sequence. A different process route can avoid literal infringement.
5) How does the 1975 issuance date affect the patent landscape?
It sets the prior art and drafting context, which usually makes the claim limitations more literal and enumerated, improving the predictability of design-around based on form, formulation, and process differences.
References
[1] United States Patent and Trademark Office. “US3888995” (patent record). USPTO Patent Center / published patent bibliographic data. https://patentscope.wipo.int/ (broad access point to patent records; use USPTO record for bibliographic verification).
[2] Google Patents. “US 3,888,995” (bibliographic data and claims text access). https://patents.google.com/
[3] USPTO. Official records for “US3888995” (title, assignee, issue date, bibliographic data). https://patents.google.com/ (redirects to USPTO source data where available).
